¼¼°èÀÇ Ä«Æ®Ç÷Π¾ÇƼ¹ÙÁ¦(¾ËÅ×ÇöóÁ¦) ½ÃÀå º¸°í¼­(2025³â) : ¿ªÇÐ, ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®, ½ÃÀå ÀλçÀÌÆ® ¹× ¿¹Ãø
Cathflo Activase (Alteplase) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts
»óǰÄÚµå : 1763064
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,310,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,121,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,932,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

īƮÇ÷Π¾ÇƼ¹ÙÁ¦(¾ËÅ×ÇöóÁ¦) ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â°£ °­ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ÀÓ»ó ÁöħÀÇ ¾÷µ¥ÀÌÆ®, Ä¡·á â È®´ë, À¯Åë °è¾à, ³óÃÌ ¹× ¿ø°Ý Áö¿ª¿¡¼­ÀÇ Ã¤Åà Áõ°¡, Ç÷Àü ¿ëÇØÁ¦ ±â¼úÀÇ ¹ßÀü µî¿¡ ±âÀÎÇÒ °ÍÀ¸·Î ºÐ¼®µË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ȯÀÚ ¼±È£µµ, Á¦³×¸¯ ÀǾàǰ, ÀÇ·á ±â¼úÀÇ ¹ßÀü, ¿ø°Ý ¸ð´ÏÅ͸µ, »ý¹°ÇÐÀû Ç÷Àü ¿ëÇØÁ¦ µîÀÌ ÀÖ½À´Ï´Ù.

½ÉÀå ¸¶ºñÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó īƮÇ÷Π¾ÇƼ¹ÙÁ¦(¾ËÅ×ÇöóÁ¦) ½ÃÀåÀÇ ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÉÀå ¸¶ºñ´Â ½ÉÀåÀ¸·Î °¡´Â Ç÷·ù°¡ ¸·Çô, º¸Åë °ü»ó µ¿¸Æ¿¡ Ç÷ÀüÀ̳ª ÇöóÅ©°¡ ½×¿© ½ÉÀå ±ÙÀ°ÀÌ ¼Õ»óµÇ°Å³ª »ç¸ÁÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. ½ÉÀå ¸¶ºñÀÇ Áõ°¡´Â °Ç°­¿¡ ÇØ·Î¿î ½Ä½À°ü, ¾É¾ÆÀÖ´Â »ýȰ ¹æ½Ä, Èí¿¬, ½ºÆ®·¹½º, ºñ¸¸ µîÀÇ ¿äÀΰú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ¾ËÅ×ÇöóÁ¦´Â Ç÷ÀüÀ» ºü¸£°Ô ¿ëÇØÇÏ¿© ½ÉÀåÀ¸·ÎÀÇ Ç÷·ù¸¦ ȸº¹ÇÏ°í ±Þ¼º Áúȯ ½Ã ±ÙÀ° ¼Õ»óÀ» ÁÙ¿© ½ÉÀå ¸¶ºñ ÇÕº´ÁõÀ» ¿¹¹æÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 10¿ù, ¹Ì±¹ Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC)´Â 2022³â¿¡ ¹Ì±¹¿¡¼­ 70¸¸ 2,880¸í ÀÌ»óÀÌ ½ÉÀå ÁúȯÀ¸·Î »ç¸ÁÇßÀ¸¸ç, ÀÌ´Â »ç¸ÁÀÚÀÇ 5ºÐÀÇ 1À» Â÷ÁöÇÑ´Ù°í º¸°íÇß½À´Ï´Ù. ¶ÇÇÑ, ¸Å³â ¾à 80¸¸ 5,000¸íÀÇ ¹Ì±¹ÀÎÀÌ ½ÉÀå ¸¶ºñ¸¦ °Þ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ½ÉÀå ¸¶ºñÀÇ ¹ßº´·üÀÌ Áõ°¡Çϸ鼭 īƮÇ÷Π¾ÇƼ¹ÙÁ¦(¾ËÅ×ÇöóÁ¦) ½ÃÀåÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯ Áõ°¡´Â īƮÇ÷Π¾ÇƼ¹ÙÁ¦(¾ËÅ×ÇöóÁ¦) ½ÃÀåÀÇ ¼ºÀåÀÌ °¡¼ÓÈ­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¸¼º ÁúȯÀº ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ¾ÇÈ­µÇ´Â °æÇâÀÌ ÀÖ´Â Àå±âÀûÀÎ °Ç°­ »óÅÂÀÔ´Ï´Ù. ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÏ´Â ¿øÀÎÀº »ýȰ ¹æ½ÄÀÇ º¯È­, ȯ°æÀû ¿µÇâ, À¯ÀüÀû ¼ÒÀÎ µî ¿©·¯ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. Cathflo Activase´Â Á¶Á÷ Çö󽺹̳ë°Õ Ȱ¼ºÈ­Á¦·Î, Á᫐ Á¤¸Æ Ä«Å×ÅÍ¿¡¼­ ¹ß»ýÇÒ ¼ö ÀÖ´Â Ç÷ÀüÀ» Ä¡·áÇÏ´Â µ¥ È¿°úÀûÀÔ´Ï´Ù. ÀÌ´Â È­Çпä¹ý, Åõ¼®, Á¤¸Æ ¿µ¾ç°ú °°Àº Çʼö Ä¡·á¿¡ Áö¼ÓÀûÀÎ Á¢±ÙÀ» º¸ÀåÇÕ´Ï´Ù. ÀÌ´Â ¸¸¼º Áúȯ ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ã۸ç, ¸·È÷°Å³ª °íÀå³­ Ä«Å×ÅÍ·Î ÀÎÇÑ ÇÕº´ÁõÀ» ÁÙÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 1¿ù ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)Àº 2050³â±îÁö ¹Ì±¹ ³» ¸¸¼º Áúȯ ȯÀÚ ¼ö°¡ 1¾ï 4,266¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸ÁÇßÀ¸¸ç, ÀÌ´Â 99.5% Áõ°¡ÇÑ ¼öÄ¡ÀÔ´Ï´Ù. µû¶ó¼­ ¸¸¼º ÁúȯÀÇ Áõ°¡ Ãß¼¼´Â īƮÇ÷Π¾ÇƼ¹ÙÁ¦(¾ËÅ×ÇöóÁ¦) ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå¿¡¼­ÀÇ Á¦Ç° Ư¼º

Á¦4Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦5Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°, °æ±â ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦6Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦7Àå ¼¼°è ½ÃÀåÀÇ °¡°Ý ºÐ¼®°ú ¿¹Ãø

Á¦8Àå ½ÃÀå ¼¼ºÐÈ­

Á¦9Àå ÀÓ»óÀûÀÀÁõ ¼¼°è ½ÃÀå ¿ªÇÐ

Á¦10Àå Áö¿ªº°, ±¹°¡º° ºÐ¼®

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦12Àå Áß±¹ ½ÃÀå

Á¦13Àå Àεµ ½ÃÀå

Á¦14Àå ÀϺ» ½ÃÀå

Á¦15Àå È£ÁÖ ½ÃÀå

Á¦16Àå Çѱ¹ ½ÃÀå

Á¦17Àå ¼­À¯·´ ½ÃÀå

Á¦18Àå ¿µ±¹ ½ÃÀå

Á¦19Àå µ¶ÀÏ ½ÃÀå

Á¦20Àå ÇÁ¶û½º ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ºÏ¹Ì ½ÃÀå

Á¦23Àå ¹Ì±¹ ½ÃÀå

Á¦24Àå ij³ª´Ù ½ÃÀå

Á¦25Àå ³²¹Ì ½ÃÀå

Á¦26Àå Áßµ¿ ½ÃÀå

Á¦27Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦28Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦29Àå ¼¼°è ½ÃÀå : ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®

Á¦30Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦31Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦32Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦33Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦34Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Alteplase, a recombinant tissue plasminogen activator (rtPA), is a therapeutic protein utilized as a thrombolytic agent for dissolving blood clots in critical conditions such as acute ischemic stroke, myocardial infarction (heart attack), and pulmonary embolism. It works by binding to fibrin in a clot, converting plasminogen into plasmin, an enzyme that degrades the fibrin matrix, thereby restoring normal blood flow and minimizing tissue damage from ischemia.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Cathflo Activase (alteplase) is available in various forms, including powder, solution, and other formulations. The powder form is specifically used as a thrombolytic agent for dissolving blood clots in central venous catheters to improve catheter function. Available dosages include 2 mg, 50 mg, and 100 mg. Distribution channels encompass hospital pharmacies, retail pharmacies, and online pharmacies. Key applications include acute ischemic stroke, acute myocardial infarction, acute massive pulmonary embolism, among others, and it is used by various end users such as clinics, hospitals, and others.

The cathflo activase (alteplase) market research report is one of a series of new reports from The Business Research Company that provides cathflo activase (alteplase) market statistics, including cathflo activase (alteplase) industry global market size, regional shares, competitors with a cathflo activase (alteplase) market share, detailed cathflo activase (alteplase) market segments, market trends and opportunities, and any further data you may need to thrive in the cathflo activase (alteplase) industry. This cathflo activase (alteplase) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cathflo activase (alteplase) market size is expected to see strong growth in the next few years. It will grow to $2,170.5 million in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to updates in clinical guidelines, extended therapeutic windows, distribution agreements, increased adoption in rural and remote areas, advancements in thrombolytic agents. Major trends in the forecast period include patient preference, generic medications, advancements in med-tech, remote monitoring, and bio better thrombolytic agents.

The increasing incidence of heart attacks is expected to drive the growth of the cathflo activase (alteplase) market. A heart attack occurs when blood flow to the heart is blocked, usually by a clot or plaque buildup in the coronary arteries, leading to damage or death of heart muscle. The rise in heart attacks is linked to factors such as unhealthy diets, sedentary lifestyles, smoking, stress, and obesity. Alteplase is crucial in preventing heart attack complications as it rapidly dissolves blood clots, restoring blood flow to the heart and reducing muscle damage during acute events. For example, in October 2024, the Centers for Disease Control and Prevention (CDC) reported that over 702,880 people died from heart disease in the U.S. in 2022, accounting for one in five deaths. Additionally, about 805,000 Americans suffer from heart attacks each year. Thus, the growing incidence of heart attacks is driving the cathflo activase (alteplase) market.

The increasing prevalence of chronic diseases is expected to fuel the growth of the cathflo activase (alteplase) market. Chronic diseases are long-term health conditions that tend to worsen over time. Their rising prevalence is attributed to factors like changing lifestyles, environmental influences, and genetic predispositions. Cathflo Activase, a tissue plasminogen activator, is effective in treating blood clots that may develop in central venous catheters, ensuring continued access to essential treatments like chemotherapy, dialysis, and intravenous nutrition. This improves the quality of life for chronic disease patients while reducing complications from blocked or malfunctioning catheters. For instance, in January 2023, the National Institutes of Health (NIH) projected that by 2050, the number of people with chronic diseases in the U.S. would reach 142.66 million, a 99.5% increase. Therefore, the rising prevalence of chronic diseases is contributing to the growth of the cathflo activase (alteplase) market.

The aging population is expected to drive the cathflo activase (alteplase) market. Aging is the natural process of growing older, often associated with a decline in bodily functions and tissue integrity. The aging population is increasing due to longer life expectancy, lower birth rates, and advancements in healthcare that have improved longevity. Cathflo Activase (alteplase) is essential for managing catheter occlusions, which are common in elderly patients. For example, in 2022, America's Health Rankings reported that the percentage of elderly people in the U.S. increased to 17.3%. Consequently, the aging population is a key factor driving the growth of the cathflo activase (alteplase) market.

Major players operating in the cathflo activase (alteplase) market are F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH.

North America was the largest region in the cathflo activase (alteplase) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cathflo activase (alteplase) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cathflo activase (alteplase) market consists of sales of powder, solution vials, injection kits, and diagnostic kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cathflo Activase (Alteplase) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cathflo activase (alteplase) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cathflo activase (alteplase) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cathflo activase (alteplase) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Cathflo Activase (Alteplase) Market Characteristics

3. Cathflo Activase (Alteplase) Market Biologic Drug Characteristics

4. Cathflo Activase (Alteplase) Market Trends And Strategies

5. Cathflo Activase (Alteplase) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Cathflo Activase (Alteplase) Growth Analysis And Strategic Analysis Framework

7. Global Cathflo Activase (Alteplase) Market Pricing Analysis & Forecasts

8. Cathflo Activase (Alteplase) Market Segmentation

9. Global Cathflo Activase (Alteplase) Market Epidemiology Of Clinical Indications

10. Cathflo Activase (Alteplase) Market Regional And Country Analysis

11. Asia-Pacific Cathflo Activase (Alteplase) Market

12. China Cathflo Activase (Alteplase) Market

13. India Cathflo Activase (Alteplase) Market

14. Japan Cathflo Activase (Alteplase) Market

15. Australia Cathflo Activase (Alteplase) Market

16. South Korea Cathflo Activase (Alteplase) Market

17. Western Europe Cathflo Activase (Alteplase) Market

18. UK Cathflo Activase (Alteplase) Market

19. Germany Cathflo Activase (Alteplase) Market

20. France Cathflo Activase (Alteplase) Market

21. Eastern Europe Cathflo Activase (Alteplase) Market

22. North America Cathflo Activase (Alteplase) Market

23. USA Cathflo Activase (Alteplase) Market

24. Canada Cathflo Activase (Alteplase) Market

25. South America Cathflo Activase (Alteplase) Market

26. Middle East Cathflo Activase (Alteplase) Market

27. Africa Cathflo Activase (Alteplase) Market

28. Cathflo Activase (Alteplase) Market Competitive Landscape And Company Profiles

29. Global Cathflo Activase (Alteplase) Market Pipeline Analysis

30. Global Cathflo Activase (Alteplase) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Cathflo Activase (Alteplase) Market

32. Recent Developments In The Cathflo Activase (Alteplase) Market

33. Cathflo Activase (Alteplase) Market High Potential Countries, Segments and Strategies

34. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â